Expand DNLI Menu
DNLI MENU

DNLI Stock Posts


Upcoming Earnings

DNLI Denali Therapeutics24.48+0.06 (+0.3%)

Denali Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±10.7% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±2.7%. View Expected Move (Conf Call: Aug 6 4:30 PM)
Unusual Option Volume

DNLI Denali Therapeutics24.94+0.12 (+0.5%)

Denali Therapeutics trades 3,237 contracts. The highest volume is in the 17-Jul-26 30 calls, which is 20.3% above the current price.
View Details...
DNLI #DenaliTherapeutics stock declines -8.8% in after hours trading. See the latest news.

After Hours Decliner

DNLI Denali Therapeutics19.30+0.47+2.5%

After Hours:17.60-1.70 (-8.8%)

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

Globe NewswireThu, 21-May 6:00 PM
Unusual Option Volume

DNLI Denali Therapeutics20.19-2.28 (-10.2%)

Denali Therapeutics trades 2,354 contracts. The company has the following event: on Apr 5, 2026.
View Details...
Unusual Option Volume

DNLI Denali Therapeutics21.85+0.88 (+4.2%)

Denali Therapeutics trades 2,640 contracts. The company has the following event: on Mar 25, 2026. News: Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
View Details...
DNLI #DenaliTherapeutics stock declines -9.5% in after hours trading. See the latest news.

After Hours Decliner

DNLI Denali Therapeutics19.66-0.03-0.2%

After Hours:17.80-1.86 (-9.5%)

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Globe NewswireTue, 9-Dec 4:01 PM
Load Earlier Posts
Market Data Delayed 15 Minutes